Image: Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, is a pioneer of generative AI for drug discovery. see more
Photo credit: Insilico Medicine
Alex Zhavoronkov, PhD, a Generative Artificial Intelligence (AI) expert for drug discovery and Founder and CEO of Insilico Medicine (“Insilico”), will be speaking at NextMed Health on March 14 at 5 p.m. PT at the Hotel Del Coronado in San Diego give a lecture. NextMed Health brings together a diverse group of healthcare professionals, entrepreneurs, academics, investors, patients and public health professionals to address significant healthcare challenges. Zhavoronkov will speak at the panel “Accelerating Cures and the Future of Pharma”.
Insilico is a leading innovator in advancing new therapeutics using generative AI and reinforcement learning and has an end-to-end Pharma.AI platform for new target identification (PandaOmics), new drug development (Chemistry42) and prediction developed based on the results of clinical studies (InClinico). The platform has produced two drugs that have reached clinical trials. Insilico’s lead drug for the devastating chronic lung disease idiopathic pulmonary fibrosis (IPF), the first AI-discovered and AI-developed drug to advance into clinical trials, will soon enter Phase 2 patient trials. And Insilico recently announced that its generative AI-developed drug for COVID-19 and related variants has been approved for clinical trials and has a number of design advantages over existing COVID-19 drugs.
There are 30 drugs in Insilico’s internal pipeline available for partnership and licensing in indications such as cancer, fibrosis and immunology, and the company has also partnered with leading pharmaceutical companies such as Fosun and Sanofi to advance their programs.
NextMed Health is focused on healthcare innovation, uniting thought leaders and disruptors from diverse fields to break down barriers to healthcare innovation across technology, care and the biomedical continuum. The event features a combination of physical and virtual gatherings and thought-provoking content and curation.
Founded in 2014, Insilico Medicine has raised over $400 million in funding from prominent biotech and tech investors and has received numerous awards, including 2022 BioCentury-BayHelix Company of the Year and Top 100 AI Companies by CB insights
About insilico medicine
Insilico Medicine, a clinical-stage Generative Artificial Intelligence (AI) drug discovery company, combines biology, chemistry and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that leverage deep generative models, reinforcement learning, transformers and other advanced machine learning techniques to discover novel targets and design novel molecular structures with desired properties. Insilico Medicine delivers breakthrough solutions to discover and develop innovative medicines for cancer, fibrosis, immunity, central nervous system disorders and age-related diseases. Insilico Medicine is headquartered in Hong Kong with additional offices in New York, Montreal, Shanghai, Suzhou, Taipei and Abu Dhabi. www.insilico.com
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the press releases published on EurekAlert! by contributing institutions or for the use of information about the EurekAlert system.
